Brain Imaging, Attention, and Auditory Processing in Schizophrenia

NCT03068806 | Completed

• 1 other identifier: MH058262
• Study Type: observational
• Target: 202
• Locations: 1 country
• Sites: 1

Brief Summary

This is a research study designed to examine how the psychiatric illness called schizophrenia affects brain function and thinking abilities such as attention and memory during simple computer-based tasks, and how measures of brain function are related to performance. The investigators do this by looking at brain activity using electroencephalography (EEG) and magnetic resonance imaging (MRI). The investigators compare participants' results to the activity in their brain as well as clinical measures and questionnaires also completed during this study.

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (3)

• EEG

  Electroencephalography, measures signals from the brain while participants conduct specific tasks that measure memory and attention.

  Day 1

• MRI

  Magnetic Resonance Imaging, measures activity in, and takes detailed pictures of the brain while participants conduct specific tasks that measure memory and attention.

  Day 1

• Memory and Attention tasks

  Tasks involve saying words, pressing buttons at specific times, listening, and viewing pictures.

  Day 1

Study Arms (2)

Patients with Schizophrenia

Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.

Diagnostic Test: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)

Healthy Controls

Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.

Diagnostic Test: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)

Interventions

Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI) DIAGNOSTIC_TEST

The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.

Healthy Controls; Patients with Schizophrenia

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who have been diagnosed with schizophrenia and meet our research criteria of symptoms indicative of a diagnosis of schizophrenia within their lifetime are eligible for this study. Healthy controls who have never met criteria for a psychiatric disorder and meet our research criteria will also be included in this study.

You may qualify if:

• The subject population will include 18 to 75 year old participants of any gender, race, and ethnicity. All subjects will be able to speak and understand English.
• Schizophrenia subjects:
• \. Patients must be diagnosed with DSM-IV schizophrenia, schizophreniform, or schizoaffective disorder based on a SCID-P interview.
• Comparison subjects:
• \. Control participants must not have past or present Axis I diagnosis as determined by the SCID-NP.

You may not qualify if:

• All subjects:
• A hearing deficit greater than 40dB in both ears detected during the hearing test
• Substance dependence, as per clinical judgment, in the past 1 year (except caffeine and nicotine)
• A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological
• History of head injury with loss of consciousness greater than 15 minutes
• Any other condition or medication, which in the opinion of the investigator would preclude participation in the study.
• Non-English speaking.
• Comparison subjects:
• \. Any first-degree relative with schizophrenia or bipolar disorder.

Sponsors & Collaborators

• San Francisco Veterans Affairs Medical Center: lead

Study Sites (1)

San Francisco VA Medical Center

San Francisco, California, 94121, United States

Location

Related Publications (41)

• Becsey L, Malamed S, Radnay P, Foldes FF. Reduction of the psychotomimetic and circulatory side-effects of ketamine by droperidol. Anesthesiology. 1972 Nov;37(5):536-42. doi: 10.1097/00000542-197211000-00016. No abstract available.

  PMID: 4562467 BACKGROUND

• Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res. 2007 Feb;90(1-3):41-51. doi: 10.1016/j.schres.2006.10.010. Epub 2006 Dec 6.

  PMID: 17156977 BACKGROUND

• Broerse A, Crawford TJ, den Boer JA. Parsing cognition in schizophrenia using saccadic eye movements: a selective overview. Neuropsychologia. 2001;39(7):742-56. doi: 10.1016/s0028-3932(00)00155-x.

  PMID: 11311304 BACKGROUND

• Clementz BA, McDowell JE, Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol. 1994 May;103(2):277-87.

  PMID: 8040497 BACKGROUND

• Crawford TJ, Sharma T, Puri BK, Murray RM, Berridge DM, Lewis SW. Saccadic eye movements in families multiply affected with schizophrenia: the Maudsley Family Study. Am J Psychiatry. 1998 Dec;155(12):1703-10. doi: 10.1176/ajp.155.12.1703.

  PMID: 9842779 BACKGROUND

• Dedovic K, Renwick R, Mahani NK, Engert V, Lupien SJ, Pruessner JC. The Montreal Imaging Stress Task: using functional imaging to investigate the effects of perceiving and processing psychosocial stress in the human brain. J Psychiatry Neurosci. 2005 Sep;30(5):319-25.

  PMID: 16151536 BACKGROUND

• Ford JM, Mathalon DH. Corollary discharge dysfunction in schizophrenia: can it explain auditory hallucinations? Int J Psychophysiol. 2005 Nov-Dec;58(2-3):179-89. doi: 10.1016/j.ijpsycho.2005.01.014. Epub 2005 Aug 31.

  PMID: 16137779 BACKGROUND

• Ford JM, Mathalon DH, Marsh L, Faustman WO, Harris D, Hoff AL, Beal M, Pfefferbaum A. P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia. Biol Psychiatry. 1999 Jul 1;46(1):94-101. doi: 10.1016/s0006-3223(98)00290-x.

  PMID: 10394478 BACKGROUND

• Fukushima J, Fukushima K, Morita N, Yamashita I. Further analysis of the control of voluntary saccadic eye movements in schizophrenic patients. Biol Psychiatry. 1990 Dec 1;28(11):943-58. doi: 10.1016/0006-3223(90)90060-f.

  PMID: 2275952 BACKGROUND

• Gordon E, Cooper N, Rennie C, Hermens D, Williams LM. Integrative neuroscience: the role of a standardized database. Clin EEG Neurosci. 2005 Apr;36(2):64-75. doi: 10.1177/155005940503600205.

  PMID: 15999901 BACKGROUND

• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996 Mar;153(3):321-30. doi: 10.1176/ajp.153.3.321.

  PMID: 8610818 BACKGROUND

• Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):767-9. doi: 10.1016/j.pnpbp.2005.04.023.

  PMID: 15939521 BACKGROUND

• Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun;60(6):572-6. doi: 10.1001/archpsyc.60.6.572.

  PMID: 12796220 BACKGROUND

• Jaeger J, Berns SM, Czobor P. The multidimensional scale of independent functioning: a new instrument for measuring functional disability in psychiatric populations. Schizophr Bull. 2003;29(1):153-68. doi: 10.1093/oxfordjournals.schbul.a006987.

  PMID: 12908671 BACKGROUND

• Katsanis J, Kortenkamp S, Iacono WG, Grove WM. Antisaccade performance in patients with schizophrenia and affective disorder. J Abnorm Psychol. 1997 Aug;106(3):468-72. doi: 10.1037//0021-843x.106.3.468.

  PMID: 9241948 BACKGROUND

• Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33. doi: 10.1007/s00213-003-1582-z. Epub 2003 Sep 2.

  PMID: 12955285 BACKGROUND

• Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 1;60(11):1231-40. doi: 10.1016/j.biopsych.2006.03.055. Epub 2006 Aug 7.

  PMID: 16893524 BACKGROUND

• Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG, Hasselmo ME, Potts GF, Shenton ME, McCarley RW. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry. 1999 Nov;56(11):1001-5. doi: 10.1001/archpsyc.56.11.1001.

  PMID: 10565499 BACKGROUND

• Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996 May;14(5):301-7. doi: 10.1016/0893-133X(95)00137-3.

  PMID: 8703299 BACKGROUND

• Mathalon DH, Ford JM. The long and the short of it: influence of interstimulus interval on auditory P300 abnormalities in schizophrenia. Clin Electroencephalogr. 2002 Jul;33(3):125-35. doi: 10.1177/155005940203300309.

  PMID: 12192662 BACKGROUND

• McDowell JE, Clementz BA. The effect of fixation condition manipulations on antisaccade performance in schizophrenia: studies of diagnostic specificity. Exp Brain Res. 1997 Jun;115(2):333-44. doi: 10.1007/pl00005702.

  PMID: 9224861 BACKGROUND

• McDowell JE, Myles-Worsley M, Coon H, Byerley W, Clementz BA. Measuring liability for schizophrenia using optimized antisaccade stimulus parameters. Psychophysiology. 1999 Jan;36(1):138-41. doi: 10.1017/s0048577299980836.

  PMID: 10098389 BACKGROUND

• Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology. 2000 Mar;22(3):293-302. doi: 10.1016/S0893-133X(99)00118-9.

  PMID: 10693157 BACKGROUND

• Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E. Preliminary validity of "integneuro": a new computerized battery of neurocognitive tests. Int J Neurosci. 2005 Nov;115(11):1549-67. doi: 10.1080/00207450590957890.

  PMID: 16223701 BACKGROUND

• Ross RG, Harris JG, Olincy A, Radant A, Adler LE, Freedman R. Familial transmission of two independent saccadic abnormalities in schizophrenia. Schizophr Res. 1998 Feb 27;30(1):59-70. doi: 10.1016/s0920-9964(97)00133-3.

  PMID: 9542789 BACKGROUND

• Sereno AB, Holzman PS. Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psychiatry. 1995 Mar 15;37(6):394-401. doi: 10.1016/0006-3223(94)00127-O.

  PMID: 7772648 BACKGROUND

• Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci. 2003 Aug 13;23(19):7407-11. doi: 10.1523/JNEUROSCI.23-19-07407.2003.

  PMID: 12917376 BACKGROUND

• Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr J. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophr Res. 2000 Oct 27;45(3):235-44. doi: 10.1016/s0920-9964(99)00193-0.

  PMID: 11042441 BACKGROUND

• Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165-79. doi: 10.1146/annurev.pharmtox.42.082701.160735.

  PMID: 11807169 BACKGROUND

• Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002 Mar 1;51(5):400-6. doi: 10.1016/s0006-3223(01)01242-2.

  PMID: 11904134 BACKGROUND

• Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000 Dec;57(12):1139-47. doi: 10.1001/archpsyc.57.12.1139.

  PMID: 11115327 BACKGROUND

• Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry. 2005 Jun 15;57(12):1493-503. doi: 10.1016/j.biopsych.2005.03.018.

  PMID: 15953485 BACKGROUND

• Kort NS, Ford JM, Roach BJ, Gunduz-Bruce H, Krystal JH, Jaeger J, Reinhart RM, Mathalon DH. Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia. Biol Psychiatry. 2017 Mar 15;81(6):514-524. doi: 10.1016/j.biopsych.2016.06.019. Epub 2016 Jul 1.

  PMID: 27647218 RESULT

• Ford JM, Roach BJ, Palzes VA, Mathalon DH. Using concurrent EEG and fMRI to probe the state of the brain in schizophrenia. Neuroimage Clin. 2016 Aug 10;12:429-41. doi: 10.1016/j.nicl.2016.08.009. eCollection 2016.

  PMID: 27622140 RESULT

• Mifsud NG, Oestreich LK, Jack BN, Ford JM, Roach BJ, Mathalon DH, Whitford TJ. Self-initiated actions result in suppressed auditory but amplified visual evoked components in healthy participants. Psychophysiology. 2016 May;53(5):723-32. doi: 10.1111/psyp.12605. Epub 2016 Jan 11.

  PMID: 26751981 RESULT

• Oestreich LK, Mifsud NG, Ford JM, Roach BJ, Mathalon DH, Whitford TJ. Subnormal sensory attenuation to self-generated speech in schizotypy: Electrophysiological evidence for a 'continuum of psychosis'. Int J Psychophysiol. 2015 Aug;97(2):131-8. doi: 10.1016/j.ijpsycho.2015.05.014. Epub 2015 May 28.

  PMID: 26027781 RESULT

• Wynn JK, Jimenez AM, Roach BJ, Korb A, Lee J, Horan WP, Ford JM, Green MF. Impaired target detection in schizophrenia and the ventral attentional network: Findings from a joint event-related potential-functional MRI analysis. Neuroimage Clin. 2015 Jul 31;9:95-102. doi: 10.1016/j.nicl.2015.07.004. eCollection 2015.

  PMID: 26448909 RESULT

• Ford JM. Studying auditory verbal hallucinations using the RDoC framework. Psychophysiology. 2016 Mar;53(3):298-304. doi: 10.1111/psyp.12457.

  PMID: 26877116 RESULT

• Mathalon DH, Sohal VS. Neural Oscillations and Synchrony in Brain Dysfunction and Neuropsychiatric Disorders: It's About Time. JAMA Psychiatry. 2015 Aug;72(8):840-4. doi: 10.1001/jamapsychiatry.2015.0483.

  PMID: 26039190 RESULT

• Wang J, Mathalon DH, Roach BJ, Reilly J, Keedy SK, Sweeney JA, Ford JM. Action planning and predictive coding when speaking. Neuroimage. 2014 May 1;91:91-8. doi: 10.1016/j.neuroimage.2014.01.003. Epub 2014 Jan 11.

  PMID: 24423729 RESULT

• Ford JM, Palzes VA, Roach BJ, Potkin SG, van Erp TG, Turner JA, Mueller BA, Calhoun VD, Voyvodic J, Belger A, Bustillo J, Vaidya JG, Preda A, McEwen SC; Functional Imaging Biomedical Informatics Research Network; Mathalon DH. Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia. Schizophr Bull. 2015 Jan;41(1):223-32. doi: 10.1093/schbul/sbu031. Epub 2014 Mar 11.

  PMID: 24619536 RESULT

MeSH Terms

Conditions

Schizophrenia

Interventions

Electroencephalography; Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, Neurological; Diagnostic Techniques and Procedures; Diagnosis; Electrodiagnosis; Tomography; Diagnostic Imaging

Study Officials

• Judith Ford, PhD

  San Francisco VA Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: FED
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Scientist and Professor of Psychiatry

Study Record Dates

• First Submitted: February 27, 2017
• First Posted: March 3, 2017
• Study Start: December 1, 2014
• Primary Completion: May 11, 2018
• Study Completion: May 11, 2018
• Last Updated: November 30, 2018

Record last verified: 2018-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)